CBLN1 and hypertensive disorder: Therapeutic strategies targeting Cer metabolism are explored, including neutral sphingomyelinase inhibitors for hypertension, dietary DHA/EPA supplementation for dyslipidemia and the pharmacological approach of the anti-diabetic, metformin.